期刊
VIRUSES-BASEL
卷 13, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/v13050757
关键词
HBV; HBVcccDNA; nuclear import; nuclear pore; DNA repair; DNA synthesis; HBV cure; HBc
类别
资金
- National French Agency for Research against HIV and Hepatitis Viruses [AAP 2019-1]
Hepatitis B virus (HBV) is a major public health concern with over 250 million people chronically infected and at high risk of liver diseases. Antiviral treatments control virus replication but cannot cure HBV due to the presence of viral circular episomal DNA in nuclei of infected cells. This DNA resists therapies and evades immune surveillance, making its eradication a prime target for HBV treatment.
Hepatitis B virus (HBV) remains a major public health concern, with more than 250 million chronically infected people who are at high risk of developing liver diseases, including cirrhosis and hepatocellular carcinoma. Although antiviral treatments efficiently control virus replication and improve liver function, they cannot cure HBV infection. Viral persistence is due to the maintenance of the viral circular episomal DNA, called covalently closed circular DNA (cccDNA), in the nuclei of infected cells. cccDNA not only resists antiviral therapies, but also escapes innate antiviral surveillance. This viral DNA intermediate plays a central role in HBV replication, as cccDNA is the template for the transcription of all viral RNAs, including pregenomic RNA (pgRNA), which in turn feeds the formation of cccDNA through a step of reverse transcription. The establishment and/or expression of cccDNA is thus a prime target for the eradication of HBV. In this review, we provide an update on the current knowledge on the initial steps of HBV infection, from the nuclear import of the nucleocapsid to the formation of the cccDNA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据